B · Normal
[Ascletis Pharmaceuticals: A new drug clinical trial application for ASC39 oral tablets to treat obesity has been submitted to the U.S. FDA] On October 26, Ascletis Pharmaceuticals announced on the Hong Kong Stock Exchange that it has submitted a new drug clinical trial application (IND) for ASC39 oral tablets to the U.S. Food and Drug Administration (FDA). ASC39 oral tablet is an oral small molecule selective amylin receptor agonist for the treatment of obesity. The company expects to launch Phase I trials in the fourth quarter of 2026.
Comments